Glia are also important in dominantly inherited neurodegenerative diseases, including amyotrophic lateral sclerosis, spinocerebellar ... the direct production of degeneration in Purkinje cells ...

A recent study of clinical and genetic characteristics in patients with hereditary spastic paraplegia highlights the difficulties of making clinicogenetic correlations in a heterogeneous group of ...

Are you searching for medications to treat 'Spinocerebellar Ataxia'? Welcome to this page which serves as an archive for medications that are relevant to the treatment of Spinocerebellar Ataxia.

Cerebellar Purkinje cell(PC) impairment cause spinocerebellar ataxiass (SCAs) but there has been few treatments. In this research, we plan to elucidate pathologic pathways from RNA expression to ...

Biohaven's drug for a genetic disease that affects the nervous system met the main study goal, sending its shares up more ...

Numerous causes for DBN are known. Familial DBN subsequent to spinocerebellar degeneration is among the most common causes of DBN. In addition to hereditary causes, causes of acquired DBN include ...

Age-related macular degeneration causes the slow loss of central vision over time but rarely causes complete blindness. Macular degeneration is the leading cause of vision loss for people over 50 ...

Macular degeneration, also known as age-related macular degeneration (AMD), is the most common form of vision loss in older ...

There’s currently no cure or way to reverse macular degeneration. But you can slow down and prevent this eye disease from worsening and affecting your vision with treatments like eye health ...

The spinocerebellar ataxias (SCAs) are dominantly inherited neurodegenerative disorders ... Our efforts have focused on addressing how increasing the number of glutamines in Ataxin 1 causes neuronal ...

With wet AMD, abnormal blood vessels grow under the macula. The wet form of age-related macular degeneration can start suddenly. You won’t feel pain, but you might notice vision problems.

(RTTNews) - Biohaven Ltd. (BHVN) Monday said its pivotal study of troriluzole in Spinocerebellar Ataxia (SCA) met its primary goal. In the pre-market trade, the company's shares were rising about ...